Why the study?
Does combined blockade of ANG II, eicosanoids, and endothelin normalize blood pressure in aging female spontaneously hypertensive rats?
Does combined blockade of ANG II, eicosanoids, and endothelin normalize blood pressure in aging female spontaneously hypertensive rats?
In aging female spontaneously hypertensive rats, combined blockade of ANG II, eicosanoids, and endothelin significantly reduces but does not normalize blood pressure, suggesting multidrug therapy and additional targets may be needed for postmenopausal hypertension.
Triple blockade fails to normalize BP in aging female SHR; leaves open need for additional targets in postmenopausal hypertension models.
Prevalence of hypertension (HT) increases in women after menopause, and there is evidence that HT is not as well controlled in postmenopausal women as men. The reasons for this are not clear but may be related to the lack of adequate blockade of the systems contributing to HT in women. This study aimed to determine the roles of three of the systems known to contribute to HT in animal studies: angiotensin II (ANG II; enalapril inhibitor), eicosanoids [1-aminobenzotriazole (1-ABT) inhibitor], and endothelin (ET(A) receptor antagonist), on blood pressure (BP) in three groups of female spontaneously hypertensive rats (SHR), aged 18 mos (postmenopausal rat, PMR). After baseline telemetry BP, three drug periods were performed for 5 days each: single blockade (ABT or enalapril), double blockade (ABT+enalapril or enalapril+ABT), and triple blockade (all 3 drugs). Controls received no treatment until the third period when they received ET(A) receptor antagonist alone. Single drug blockade reduced BP in PMR to similar levels. Double blockade reduced mean arterial pressure more in ABT+enalapril rats than in the other group (enalapril+ABT). Triple drug blockade reduced BP to similar levels in both groups, but the BP remained ∼110 mmHg. The data suggest that these three systems, ANG II, eicosanoids, and endothelin, contribute together and independently to BP control in old female SHR. However, other systems also contribute to the HT since the BP was not normalized, supporting the notion that HT in postmenopausal women may require complex multidrug therapy to be better controlled and that may require the development of additional drugs.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: